Australian officials mum on details of drug stockpile purchase

06/3/2004 | Australian (tiered subscription model), The

The Australian government cited national security considerations in refusing to release details of its no-bid, multi-million dollar purchase of an antiviral medicine stockpile for use in case of a flu pandemic. The government decided to purchase Tamiflu, rather than Relenza, which was developed by Biota, a small Melbourne biotech firm. Biota has filed suit against GlaxoSmithKline, alleging the company failed to adequately promote Relenza under a licensing agreement.

View Full Article in:

Australian (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC